Company Description
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders.
The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances.
Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy.
The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications.
The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | George Magrath M.B.A., M.D., M.S. |
Contact Details
Address: 37000 Grand River Ave., Suite 120 Farmington Hills, Michigan 48335 United States | |
| Phone | 248-681-9815 |
| Website | ocuphire.com |
Stock Details
| Ticker Symbol | OCUP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001228627 |
| CUSIP Number | 67577R102 |
| ISIN Number | US67577R1023 |
| Employer ID | 11-3516358 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| George Magrath M.B.A., M.D., M.S. | Chief Executive Officer and Director |
| Bernhard Hoffmann M.B.A. | Senior Vice President of Corporate Development and Secretary |
| Dr. Jay S. Pepose M.D., Ph.D. | Chief Medical Advisor and Director |
| Amy Zaremba Rabourn C.P.A., MAcc | Senior Vice President of Finance |
| Nirav Suresh Jhaveri C.F.A. | Chief Financial Officer |
| Joseph K. Schachle MBA | Chief Operating Officer |
| Dr. Ashwath Jayagopal Ph.D. | Chief Scientific and Development Officer |
| Bindu Manne | Head of Market Development and Commercialization |
| Erik Sims | Director and Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 13, 2024 | 8-K | Current Report |
| May 30, 2024 | DEFR14A | Filing |
| May 10, 2024 | 10-Q | Quarterly Report |
| May 10, 2024 | 8-K | Current Report |
| May 10, 2024 | 8-K | Current Report |
| Apr 29, 2024 | ARS | Filing |
| Apr 29, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 19, 2024 | PRE 14A | Other preliminary proxy statements |
| Apr 17, 2024 | 8-K | Current Report |